StockData
Viking Therapeutics, Inc. logo

Viking Therapeutics, Inc. (VKTX) stock

VKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/30
$26.88+0.08 (+0.30%)

Close on Nov 17, 2026Market cap $3.43BP/E –Yield –

Viking Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Viking Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $586.17M, up 163.5% year over year. For fiscal 2025 it was $344.96M, up 239.4% from the year before. Over ten years it grew 47.7% a year on average. The highest annual figure on record is $344.96M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$344.96M+239.4%
FY2024Dec 31, 2024$101.64M+59.3%
FY2023Dec 31, 2023$63.81M+17.6%
FY2022Dec 31, 2022$54.23M+20.6%
FY2021Dec 31, 2021$44.98M+40.9%
FY2020Dec 31, 2020$31.93M+35.5%
FY2019Dec 31, 2019$23.56M+23.7%
FY2018Dec 31, 2018$19.04M+38.6%
FY2017Dec 31, 2017$13.74M+52.7%
FY2016Dec 31, 2016$9.00M+29.2%
FY2015Dec 31, 2015$6.97M-68.7%
FY2014Dec 31, 2014$22.22M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$166.80M+85.4%
Q2 FY2026Jun 30, 2026$115.75M+92.4%
Q1 FY2026Mar 31, 2026$150.15M+262.8%
Q4 FY2025Dec 31, 2025$153.46M+395.2%
Q3 FY2025Sep 30, 2025$89.95M+294.8%
Q2 FY2025Jun 30, 2025$60.15M+153.1%
Q1 FY2025Mar 31, 2025$41.39M+71.7%
Q4 FY2024Dec 31, 2024$30.99M+51.1%
Q3 FY2024Sep 30, 2024$22.79M+24.0%
Q2 FY2024Jun 30, 2024$23.77M+70.8%
Q1 FY2024Mar 31, 2024$24.10M+119.0%
Q4 FY2023Dec 31, 2023$20.50M+26.7%
Q3 FY2023Sep 30, 2023$18.38M+53.7%
Q2 FY2023Jun 30, 2023$13.92M+2.8%
Q1 FY2023Mar 31, 2023$11.01M-12.3%
Q4 FY2022Dec 31, 2022$16.18M+64.3%
Q3 FY2022Sep 30, 2022$11.96M+10.8%
Q2 FY2022Jun 30, 2022$13.54M+5.8%
Q1 FY2022Mar 31, 2022$12.56M+8.8%
Q4 FY2021Dec 31, 2021$9.85M+8.8%
Q3 FY2021Sep 30, 2021$10.80M+51.7%
Q2 FY2021Jun 30, 2021$12.80M+64.6%
Q1 FY2021Mar 31, 2021$11.54M+44.4%
Q4 FY2020Dec 31, 2020$9.05M+40.3%
Q3 FY2020Sep 30, 2020$7.12M+34.8%
Q2 FY2020Jun 30, 2020$7.78M+6.1%
Q1 FY2020Mar 31, 2020$7.99M+77.6%
Q4 FY2019Dec 31, 2019$6.45M+26.8%
Q3 FY2019Sep 30, 2019$5.28M-7.2%
Q2 FY2019Jun 30, 2019$7.33M+40.5%
Q1 FY2019Mar 31, 2019$4.50M+47.7%
Q4 FY2018Dec 31, 2018$5.09M+67.8%
Q3 FY2018Sep 30, 2018$5.69M+64.1%
Q2 FY2018Jun 30, 2018$5.22M+40.5%
Q1 FY2018Mar 31, 2018$3.04M-13.7%
Q4 FY2017Dec 31, 2017$3.03M+14.6%
Q3 FY2017Sep 30, 2017$3.47M–
Q2 FY2017Jun 30, 2017$3.72M–
Q1 FY2017Mar 31, 2017$3.53M–
Q4 FY2016Dec 31, 2016$2.65M–

More Viking Therapeutics figures

See a number that looks wrong?